
Liliana Montella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5457252/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. Oncologist, 2010, 15, 85-92.	1.9	162
2	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. Journal of Clinical Oncology, 2010, 28, 543-548.	0.8	142
3	Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer, 2002, 94, 1414-1420.	2.0	104
4	Phase 2 trial of temozolomide using protracted lowâ€dose and wholeâ€brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer, 2008, 113, 2524-2531.	2.0	88
5	Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 301-306.	1.1	84
6	Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemotherapy and Pharmacology, 2010, 66, 837-844.	1.1	73
7	Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. BMC Cancer, 2007, 7, 18.	1.1	72
8	Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Frontiers in Bioscience - Landmark, 2007, 12, 757.	3.0	70
9	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemotherapy and Pharmacology, 2006, 57, 34-39.	1.1	66
10	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. Journal of Neuro-Oncology, 2011, 102, 417-424.	1.4	60
11	Imatinib Mesylate for Cerebral Langerhans'-Cell Histiocytosis. New England Journal of Medicine, 2004, 351, 1034-1035.	13.9	45
12	Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia. Blood, 2003, 101, 3106-3108.	0.6	40
13	Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65Âyears of age. Cancer Chemotherapy and Pharmacology, 2008, 62, 285-292.	1.1	39
14	Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemotherapy and Pharmacology, 2012, 70, 603-609.	1.1	34
15	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. Future Oncology, 2014, 10, 2141-2147.	1.1	30
16	Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 224-226.	0.6	27
17	Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series. Oncology, 2013, 84, 265-272.	0.9	27
18	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?. World Journal of Gastroenterology, 2016, 22, 6114.	1.4	27

LILIANA MONTELLA

#	Article	IF	CITATIONS
19	Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. Cancer Chemotherapy and Pharmacology, 2010, 65, 1137-1143.	1.1	26
20	Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. Journal of Bone and Mineral Metabolism, 2009, 27, 110-113.	1.3	24
21	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). Annals of Hematology, 2005, 84, 192-193.	0.8	18
22	Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Supportive Care in Cancer, 2008, 16, 209-214.	1.0	18
23	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. Future Oncology, 2017, 13, 415-423.	1.1	18
24	Functional imaging of Langerhans cell histiocytosis by111In-DTPA-D-Phe1-octreotide scintigraphy. Cancer, 2002, 94, 633-640.	2.0	17
25	Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin. Experimental and Molecular Medicine, 2004, 36, 268-273.	3.2	16
26	Thymoma followed by paroxysmal nocturnal hemoglobinuria: A unique clinical association in the context of multiorgan autoimmunity with a potential role for CD8+ T lymphocytes. American Journal of Hematology, 2006, 81, 774-778.	2.0	15
27	Conditions Suggesting Lymphoma. Journal of Clinical Oncology, 2005, 23, 3844-3846.	0.8	12
28	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. Biomedicines, 2022, 10, 150.	1.4	11
29	Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. Journal of Experimental and Clinical Cancer Research, 2009, 28, 7.	3.5	8
30	Latest developments in targeted therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1635-1646.	1.1	8
31	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1283-1288.	1.1	8
32	Somatostatin receptor expression in thymic tumors. Frontiers in Bioscience - Landmark, 2009, Volume, 3304.	3.0	7
33	Squamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer. Oncology Letters, 2014, 8, 235-237.	0.8	6
34	Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. Oncology, 2018, 95, 353-359.	0.9	6
35	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. Cancers, 2021, 13, 2359.	1.7	6
36	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells, 2021, 10, 1909.	1.8	6

LILIANA MONTELLA

#	Article	IF	CITATIONS
37	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. Chemotherapy, 2019, 64, 48-56.	0.8	5
38	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. CNS Oncology, 2019, 8, CNS32.	1.2	5
39	Atypical Cutaneous Lymphoid Hyperplasia Induced by Chemotherapy in a Patient with Advanced Colon Carcinoma. Clinical Colorectal Cancer, 2007, 6, 728-730.	1.0	4
40	Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. Cancers, 2021, 13, 2339.	1.7	4
41	Fatal Immunodeficiency in a Patient with Thymoma and Good's Syndrome. Tumori, 2005, 91, 361-363.	0.6	3
42	The Era of Targeted Therapies. Archives of Dermatology, 2007, 143, 788-9.	1.7	3
43	Fatal immunodeficiency in a patient with thymoma and Good's syndrome. Tumori, 2005, 91, 361-3.	0.6	3
44	Unusual Aspects of Melanoma. Journal of Clinical Oncology, 2004, 22, 743-744.	0.8	1
45	Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling. Biomedicines, 2021, 9, 1759.	1.4	1
46	The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?. Cancers, 2022, 14, 774.	1.7	1
47	Complementary Treatments in Thymic Neoplasms: Steroids and Octreotide. , 2008, , 241-246.		0